Juan Pablo Sánchez-Luna

Juan Pablo Sánchez-Luna

Auto-generated profile, based on publicly available information

Juan Pablo Sánchez-Luna

Cardiology Department, Hospital Clínico Universitario de Valladolid, 47003 Valladolid, Spain

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 December 2023 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
SBSara Blasco-Turrión
Sara Blasco-Turrión
Kasparas BriedisKasparas Briedis
Kasparas Briedis
RERodrigo Estévez-Loureiro
Rodrigo Estévez-Loureiro
ASAngel Sánchez-Recalde
Angel Sánchez-Recalde
ICIgnacio Cruz-González
Ignacio Cruz-González
Ignacio J. Amat-SantosIgnacio J. Amat-Santos
Ignacio J. Amat-Santos

2 September 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
SBSara Blasco-Turrión
Sara Blasco-Turrión
AFANA MARIA SERRADOR FRUTOS
ANA MARIA SERRADOR FRUTOS
JJJohn Jose
John Jose
GSGunasekaran Sengotuvelu
Gunasekaran Sengotuvelu
ASAshok Seth
Ashok Seth
Ignacio J. Amat-SantosIgnacio J. Amat-Santos
Ignacio J. Amat-Santos
Background: The vast majority of transcatheter valve-in-valve (ViV) mitral procedures have been reported with the SAPIEN family. We aimed to report the preliminary experience with the Myval balloon-expandable device in this setting. Methods: Multicenter retrospective study of high-risk surgical patients with mitral bioprosthesis degeneration undergoing transcatheter ViV implantation with Myval device. Results: A total of 11 patients from five institutions were gathered between 2019 and 2022 (age 68 ± 7.8, 63% women). The peak and mean transvalvular gradients were 27 ± 5 mmHg and 14.7 ± 2.3 mmHg, respectively, and the predicted neo-left ventricular outflow tract (neo-LVOT) area was 183.4 ± 56 mm2 (range: 171 to 221 mm2). The procedures were performed via transfemoral access in all cases (through echocardiography-guided transeptal puncture (81.8% transesophageal, 11.2% intracardiac)). Technical success was achieved in all cases, with no significant residual mitral stenosis in any of them (peak 7.2 ± 2.7 and mean gradient 3.4 ± 1.7 mmHg) and no complications during the procedure. There were no data of LVOT obstruction, migration, or paravalvular leak in any case. Mean hospital stay was 3 days, with one major vascular complication and no stroke. At 6-month follow-up, there was one case with suboptimal anticoagulation presenting an increase in the transmitral gradients (mean 15 mmHg) that normalized after optimization of the anticoagulation, but no other relevant events. Conclusions: Transseptal ViV mitral implantation with the balloon-expandable Myval device was feasible and safe avoiding redo surgery in high-risk patients with bioprosthesis degeneration.

Verified
Journal Article
Open access
PDF file
Ignacio J. Amat-SantosIgnacio J. Amat-Santos
Ignacio J. Amat-Santos
GMGiorgio Marengo
Giorgio Marengo
JSJuan Pablo Sánchez-Luna
Juan Pablo Sánchez-Luna
CVCarlos Cortés Villar
Carlos Cortés Villar
FRFERNANDO RIVERO
FERNANDO RIVERO
JCJosé Alberto San Román Calvar
José Alberto San Román Calvar
Background: Quantitative flow ratio (QFR) virtual angioplasty with pre-PCI residual QFR showed better results compared with an angiographic approach to assess post-PCI functional results. However, correlation with pre-PCI residual QFR and post-PCI fractional flow reserve (FFR) is lacking. Methods: A multicenter prospective study including consecutive patients with angiographically 50–90% coronary lesions and positive QFR results. All patients were evaluated with QFR, hyperemic and non-hyperemic pressure ratios (NHPR) before and after the index PCI. Pre-PCI residual QFR (virtual angioplasty) was calculated and compared with post-PCI fractional flow reserve (FFR), QFR and NHPR. Results: A total of 84 patients with 92 treated coronary lesions were included, with a mean age of 65.5 ± 10.9 years and 59% of single vessel lesions being the left anterior descending artery in 69%. The mean vessel diameter was 2.82 ± 0.41 mm. Procedural success was achieved in all cases, with a mean number of implanted stents of 1.17 ± 0.46. The baseline QFR value was 0.69 ± 0.12 and baseline FFR and NHPR were 0.73 ± 0.08 and 0.82 ± 0.11, respectively. Mean post-PCI FFR increased to 0.87 ± 0.05 whereas residual QFR had been estimated as 0.95 ± 0.05, showing poor correlation with post-PCI FFR (0.163; 95% CI:0.078–0.386) and low diagnostic accuracy (30.9%, 95% CI:20–43%). Conclusions: In this analysis, the results of QFR-based virtual angioplasty did not seem to accurately correlate with post-PCI FFR.

1 January 2024 in Journal of Interventional Cardiology
Verified
Journal Article
Open access
Ignacio J. Amat-SantosIgnacio J. Amat-Santos
Ignacio J. Amat-Santos
GMGiorgio Marengo
Giorgio Marengo
LYLuiz F. Ybarra
Luiz F. Ybarra
JFJose Antonio Fernández-Diaz
Jose Antonio Fernández-Diaz
ARAnder Regueiro
Ander Regueiro
SRStéphane Rinfret
Stéphane Rinfret
Background. Chronic total occlusion (CTO) plaque modification (CTO‐PM) is often used for unsuccessful CTO interventions. Methods. A multicenter, prospective study included consecutive patients with failed CTO recanalization. At the end of the failed procedure, patients received either a conventional (CB) or drug‐coated balloon (DCB) for CTO‐PM at the operator’s discretion and underwent a new attempt of CTO recanalization ∼3 months later. Results. A total of 55 patients were enrolled (DCB: 22; CB: 33), with a median age of 66 years. The median J‐score was 3, and CCS angina classes III–IV were present in 45% of the patients. After the first CTO‐PCI attempt, no in‐hospital cardiac deaths were registered. The overall rate of in‐hospital myocardial infarction was 3.6%, without significant differences between the DCB and CB groups (4.5% after DCB vs 3.0% after CB, p = 0.999). The success rate of the second CTO‐PCI attempt was 86.8%, with a periprocedural complication rate of 5.7% and with an overall rate of in‐hospital complications of 24.5%, without significant differences between the 2 groups (13.6% in the DCB group vs 32.2% in the CB group, p = 0.195). Compared with CB, in the DCB group, the second CTO‐PCI required a shorter median fluoroscopy time (33 vs 60 min, p < 0.001), a lower contrast volume (170 vs 321 cc, p < 0.001), and a lower radiation dose (1.7 vs 3.3 Gy, p < 0.001). At 1‐year follow‐up, outcomes were comparable between the 2 strategies, target vessel failure occurred in 5.7% and major adverse cardiovascular events in 18.2% (13.6% in the DCB group vs 21.2% in the CB group, p = 0.494). Conclusions. PM after CTO recanalization failure is safe and warrants high success rates when a second attempt is performed. A DCB strategy for CTO‐PM does not seem to ensure higher success or better clinical outcomes, but its use was associated with simpler staged procedures. This trial is registered with NCT05158686.

1 January 2024 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Closed access
GMGiorgio Marengo
Giorgio Marengo
CCCarlos Cortés
Carlos Cortés
JSJuan Pablo Sánchez-Luna
Juan Pablo Sánchez-Luna
JGJose Carlos Gonzalez-Gutiérrez
Jose Carlos Gonzalez-Gutiérrez
JHJavier Gómez Herrero
Javier Gómez Herrero
Ignacio J. Amat-SantosIgnacio J. Amat-Santos
Ignacio J. Amat-Santos

1 March 2024 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Closed access
Ignacio J. Amat-SantosIgnacio J. Amat-Santos
Ignacio J. Amat-Santos
GMGiorgio Marengo
Giorgio Marengo
CCCarlos Cortés
Carlos Cortés
JSJuan Pablo Sánchez-Luna
Juan Pablo Sánchez-Luna
JGJose Carlos Gonzalez-Gutiérrez
Jose Carlos Gonzalez-Gutiérrez
JCJosé Alberto San Román Calvar
José Alberto San Román Calvar